Lysogene S.A.
PAR: LYS.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Karen Pignet-Aiach MBA
- Employees
- 22
- Headquarters
- Neuilly-sur-Seine, France
- IPO year
- 2017
- Market cap
- €4.9M
- Website
- https://www.lysogene.com
Loading LYS…
Loading profile data…Frequently asked questions about LYS
What does Lysogene S.A. (LYS.PA) do?
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II...
Where does LYS.PA trade?
Lysogene S.A. (LYS.PA) trades on the Euronext Paris.
What sector is LYS.PA in?
Lysogene S.A. (LYS.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lysogene S.A.?
Karen Pignet-Aiach MBA is the chief executive officer of Lysogene S.A. (LYS.PA).
Where is Lysogene S.A. headquartered?
Lysogene S.A. is headquartered in France.
Does LYS.PA pay a dividend?
Lysogene S.A. (LYS.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LYS.PA go public?
Lysogene S.A. (LYS.PA) completed its initial public offering in 2017.